Cart
sales@molnova.com
CDK8-IN-12
CAS No. 2613307-67-6
CDK8-IN-12( —— )
Catalog No. M36414 CAS No. 2613307-67-6
CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 112 | In Stock |
|
| 5MG | 98 | In Stock |
|
| 10MG | 145 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 355 | In Stock |
|
| 100MG | 498 | In Stock |
|
| 200MG | 681 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK8-IN-12
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent.
-
DescriptionCDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with Kis of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent.
-
In VitroWestern Blot Analysis Cell Line:MV4-11 cells Concentration:0.36, 0.72 μM Incubation Time:2 hours Result:Significantly reduced the phosphorylation of serine 727 on STAT1 at concentrations of their respective 1× GI50 values, but barely affected the level of total STAT1.
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3 | CDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2613307-67-6
-
Formula Weight381.86
-
Molecular FormulaC21H20ClN3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C2(CCN(CC2)C=3C(=CN=CC3Cl)C4=CC=5C(O4)=CC=CC5)CCN1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mingfeng Yu, et al. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation. Eur J Med Chem. 2021 Mar 15;214:113248.?
molnova catalog
related products
-
BRD0209
BRD0209 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 19 nM/5 nM for GSK3α/GSK3β respectively.
-
GSK-3β inhibitor 11
GSK-3β inhibitor 11 (compound 21) is a potent glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 10.02 μM, demonstrating potential utility in neurodegenerative disease research .
-
GSK-3β inhibitor 1 (...
GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy.
